Work

Preliminary efficacy and safety of lorlatinib in patients (Pts) with ROS1-positive non-small cell lung cancer (NSCLC)

Year: 2017

Type: article

Source: Annals of Oncology

DOI: 10.1093/annonc/mdx380.011

Authors: B. Besse, A.T. Shaw, B.J. Solomon, T.M. Bauer, R. Chiari, C-C. Lin, M. Satouchi, J.S. Clancy, L.P. James, A. Abbattista, E. Felip Font

Institutions: Institut Gustave Roussy, Massachusetts General Hospital, Peter MacCallum Cancer Centre, Sarah Cannon, Azienda Ospedaliera di Perugia, National Taiwan University Hospital, Hyogo Prefectural Cancer Center, Pfizer (United States), Pfizer (Italy), Vall d'Hebron Institute of Oncology

Language: English

Topic: Lung Cancer Treatments and Mutations

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

Funders: Bristol-Myers Squibb, Eli Lilly and Company, Pfizer, AstraZeneca, Institut Gustave-Roussy

OpenAlex ID: W2764025876

FWCI: 0.405

Cites:

Cited by: 2

Related to: 10